Watch KPHMW. Know when insiders buy.
One email the day a filing lands. Free.
KPHMW
KIORA PHARMACEUTICALS INC
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$11MNET CASH $6.8M52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$2.2M | −$2.1M | — | -0.34 | −$1.9M | $23K | −$1.9M | Aug 7 |
| Q1 2026 · Mar 31 | — | — | — | −$2.5M | −$2.4M | — | -0.58 | −$3.2M | $5K | −$3.2M | May 8 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$7.3M | −$6.5M | — | -1.60 | −$2.2M | $78K | −$2.3M | Mar 25 |
| Q3 2025 · Sep 30 | $0 | — | — | −$794K | $27K | — | 0.01 | −$1.3M | $431 | −$1.3M | Nov 7 |
| Q2 2025 · Jun 30 | $0 | −100.0% | — | −$2.4M | −$2.2M | — | -0.54 | −$3.8M | $32K | −$3.8M | Aug 7 |
| Q1 2025 · Mar 31 | $0 | −100.0% | — | −$2.3M | −$2.2M | −116.3% | -0.52 | −$2.7M | $0 | −$2.7M | May 8 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$2.6M | −$4.2M | — | -1.04 | −$2.3M | −$45K | −$2.2M | Mar 25 |
| Q3 2024 · Sep 30 | $0 | — | — | −$3.6M | −$3.4M | — | -0.81 | $920K | $0 | $920K | Nov 7 |
| Q2 2024 · Jun 30 | $20K | — | — | −$2.5M | −$2.2M | — | -0.53 | −$3.7M | — | — | Aug 8 |
| Q1 2024 · Mar 31 | $16M | — | — | $13.2M | $13.5M | — | 3.46 | $13.6M | — | — | May 9 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$2.1M | −$2.3M | — | -0.90 | −$2.6M | $0 | −$2.6M | Mar 25 |
| Q3 2023 · Sep 30 | $0 | — | — | −$5.9M | −$5.8M | — | -7.30 | −$2.5M | $0 | −$2.5M | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$12.8M | −$10.8M | — | -2.64 | −$10M | $111K | −$10.1M | — | — |
| FY2024 · to Dec 31 | $16M | — | $4.5M | $3.6M | 22.4% | 0.87 | $8.6M | $6K | $8.6M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$12.6M | −$12.5M | — | -24.25 | −$9.6M | $0 | −$9.6M | — | — |
| FY2022 · to Dec 31 | — | — | −$12.3M | −$13.6M | — | -18.55 | −$10.4M | $0 | −$10.4M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$14.2M | −$13.8M | — | -57.12 | −$10.7M | $64K | −$10.7M | — | — |
| FY2020 · to Dec 31 | $12K | — | −$6.9M | −$6.9M | -56901.7% | -1.49 | −$7.3M | $20K | −$7.3M | — | — |
Every number comes from KIORA PHARMACEUTICALS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.